Mizuho analyst Vikram Malhotra downgraded Sabra Health Care (SBRA) to Neutral from Outperform with an unchanged price target of $20. The firm says multiples in the skilled nursing facility group “reflect a perfect set-up amid higher regulatory risk.” From being outright positive on the group, Mizuho is now neutral.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: